JAK-STAT signaling in the regulation of Beta-cells

No Pathway Network information available for JAK-STAT signaling in the regulation of Beta-cells

Pathways in the JAK-STAT signaling in the regulation of Beta-cells SuperPath

#	Name	Source	Genes
1	JAK-STAT signaling in the regulation of Beta-cells	WikiPathways	AKT1 AKT1S1 AKT2 AKT3 CCND1 CCND2 CCND3 CDK4 CISH EPO EPOR FOXM1 GH1 GHR HRAS IFNG IFNGR1 IFNGR2 IL6 IL6R JAK2 KRAS MLST8 MTOR NRAS PRL PRLR RPTOR SOCS1 SOCS2 SOCS3 STAT1 STAT3 STAT5A STAT5B (see all 35) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	SOCS3	Suppressor Of Cytokine Signaling 3	Protein Coding	1
2	CCND3	Cyclin D3	Protein Coding	1
3	CCND2	Cyclin D2	Protein Coding	1
4	SOCS2	Suppressor Of Cytokine Signaling 2	Protein Coding	1
5	SOCS1	Suppressor Of Cytokine Signaling 1	Protein Coding	1
6	AKT1S1	AKT1 Substrate 1	Protein Coding	1
7	STAT5B	Signal Transducer And Activator Of Transcription 5B	Protein Coding	1
8	STAT5A	Signal Transducer And Activator Of Transcription 5A	Protein Coding	1
9	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	1
10	STAT1	Signal Transducer And Activator Of Transcription 1	Protein Coding	1
11	CCND1	Cyclin D1	Protein Coding	1
12	RPTOR	Regulatory Associated Protein Of MTOR Complex 1	Protein Coding	1
13	PRLR	Prolactin Receptor	Protein Coding	1
14	PRL	Prolactin	Protein Coding	1
15	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	1
16	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1
17	JAK2	Janus Kinase 2	Protein Coding	1
18	IL6R	Interleukin 6 Receptor	Protein Coding	1
19	IL6	Interleukin 6	Protein Coding	1
20	IFNGR2	Interferon Gamma Receptor 2	Protein Coding	1
21	IFNGR1	Interferon Gamma Receptor 1	Protein Coding	1
22	IFNG	Interferon Gamma	Protein Coding	1
23	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	1
24	GHR	Growth Hormone Receptor	Protein Coding	1
25	GH1	Growth Hormone 1	Protein Coding	1
26	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	1
27	FOXM1	Forkhead Box M1	Protein Coding	1
28	AKT2	AKT Serine/Threonine Kinase 2	Protein Coding	1
29	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	1
30	EPOR	Erythropoietin Receptor	Protein Coding	1
31	EPO	Erythropoietin	Protein Coding	1
32	CISH	Cytokine Inducible SH2 Containing Protein	Protein Coding	1
33	CDK4	Cyclin Dependent Kinase 4	Protein Coding	1
34	AKT3	AKT Serine/Threonine Kinase 3	Protein Coding	1
35	MLST8	MTOR Associated Protein MLST8	Protein Coding	1

Disorders associated with JAK-STAT signaling in the regulation of Beta-cells SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Schimmelpenning-feuerstein-mims syndrome	Enrichment	HRAS, KRAS, NRAS	7.20
2	Nevus, epidermal	Enrichment	HRAS, KRAS, NRAS	6.26
3	Lung non-small cell carcinoma	Enrichment	HRAS, KRAS, NRAS	5.59
4	Ras-associated autoimmune leukoproliferative disorder	Enrichment	KRAS, NRAS	5.19
5	Noonan syndrome and noonan-related syndrome	Enrichment	HRAS, KRAS, NRAS	5.15
6	Large congenital melanocytic nevus	Enrichment	HRAS, NRAS	4.71
7	Breast implant-associated anaplastic large cell lymphoma	Enrichment	JAK2, STAT3	4.71
8	Noonan syndrome 1	Enrichment	HRAS, KRAS, NRAS	4.57
9	Erythrocytosis, familial, 1	Enrichment	EPOR, JAK2	4.41
10	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1	Enrichment	AKT3, CCND2	4.41
11	Chronic myelogenous leukemia, bcr-abl1 positive	Enrichment	KRAS, NRAS	4.41
12	Rasopathy	Enrichment	HRAS, KRAS, NRAS	4.41
13	Differentiated thyroid carcinoma	Enrichment	HRAS, KRAS, NRAS	4.26
14	Hemimegalencephaly	Enrichment	AKT3, MTOR	4.19
15	Breast adenocarcinoma	Enrichment	AKT1, KRAS	4.02
16	Thyroid cancer, nonmedullary, 2	Enrichment	HRAS, NRAS	3.87
17	Leukemia, chronic myeloid	Enrichment	KRAS, NRAS	3.87
18	Noonan syndrome 3	Enrichment	HRAS, KRAS	3.87
19	Follicular thyroid carcinoma	Enrichment	HRAS, NRAS	3.87
20	Leukemia, acute myeloid	Enrichment	JAK2, KRAS, NRAS	3.84
21	Melanocytic nevus syndrome, congenital	Enrichment	HRAS, NRAS	3.75
22	Juvenile myelomonocytic leukemia	Enrichment	KRAS, NRAS	3.38
23	Acute promyelocytic leukemia	Enrichment	STAT3, STAT5B	3.30
24	Arteriovenous malformations of the brain	Enrichment	IL6, KRAS	2.97
25	Diffuse large b-cell lymphoma	Enrichment	SOCS1, STAT3	2.97
26	Colorectal cancer	Enrichment	AKT1, CCND1, NRAS	2.84
27	Bladder cancer	Enrichment	HRAS, KRAS	2.60
28	Proteus syndrome	Enrichment	AKT1	2.59
29	Hypoinsulinemic hypoglycemia with hemihypertrophy	Enrichment	AKT2	2.59
30	Oculoectodermal syndrome	Enrichment	KRAS	2.59
31	Helicobacter pylori infection	Enrichment	IFNGR1	2.59
32	Melanoma, cutaneous malignant 3	Enrichment	CDK4	2.59
33	Dermatitis, atopic, 4	Enrichment	SOCS3	2.59
34	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3	Enrichment	CCND2	2.59
35	Melanosis, neurocutaneous	Enrichment	NRAS	2.59
36	Multiple fibroadenomas of the breast	Enrichment	PRLR	2.59
37	Noonan syndrome 6	Enrichment	NRAS	2.59
38	Microvascular complications of diabetes 2	Enrichment	EPO	2.59
39	Immunodeficiency 27a	Enrichment	IFNGR1	2.59
40	Immunodeficiency 69	Enrichment	IFNG	2.59
41	Growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant	Enrichment	STAT5B	2.59
42	Laron syndrome	Enrichment	GHR	2.59
43	T-cell large granular lymphocyte leukemia	Enrichment	STAT3	2.59
44	Hyperprolactinemia	Enrichment	PRLR	2.59
45	Growth hormone insensitivity, partial	Enrichment	GHR	2.59
46	Cardiofaciocutaneous syndrome 2	Enrichment	KRAS	2.59
47	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2	Enrichment	AKT3	2.59
48	Immunodeficiency 27b	Enrichment	IFNGR1	2.59
49	Interleukin 6, serum level of, quantitative trait locus	Enrichment	IL6R	2.59
50	Immunodeficiency 31a	Enrichment	STAT1	2.59
51	Soluble interleukin-6 receptor, serum level of, quantitative trait locus	Enrichment	IL6R	2.59
52	Cowden syndrome 6	Enrichment	AKT1	2.59
53	Hyper-ige syndrome 5, autosomal recessive, with recurrent infections	Enrichment	IL6R	2.59
54	Immunodeficiency 31b	Enrichment	STAT1	2.59
55	Erythrocytosis, familial, 5	Enrichment	EPO	2.59
56	Autoimmune disease, multisystem, infantile-onset, 1	Enrichment	STAT3	2.59
57	Capillary hemangioma	Enrichment	AKT3	2.59
58	Familial hyperprolactinemia	Enrichment	PRLR	2.59
59	Stat3-related early-onset multisystem autoimmune disease	Enrichment	STAT3	2.59
60	Congenital pulmonary airway malformation	Enrichment	KRAS	2.59
61	Phakomatosis pigmentokeratotica	Enrichment	HRAS	2.59
62	Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency	Enrichment	IFNGR2	2.59
63	Chronic lymphoproliferative disorder of natural killer cells	Enrichment	STAT3	2.59
64	Neurocutaneous melanocytosis	Enrichment	NRAS	2.59
65	Akt2-related familial partial lipodystrophy	Enrichment	AKT2	2.59
66	Non-immune hydrops fetalis	Enrichment	HRAS, KRAS	2.54
67	Costello syndrome	Enrichment	HRAS	2.29
68	Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive	Enrichment	STAT5B	2.29
69	Encephalocraniocutaneous lipomatosis	Enrichment	KRAS	2.29
70	Growth hormone deficiency, isolated partial	Enrichment	GHR	2.29
71	Thrombocythemia 3	Enrichment	JAK2	2.29
72	Immunodeficiency 31c	Enrichment	STAT1	2.29
73	Diamond-blackfan anemia-like	Enrichment	EPO	2.29
74	Cebalid syndrome	Enrichment	MTOR	2.29
75	Kowarski syndrome	Enrichment	GH1	2.29
76	Senior-loken syndrome 7	Enrichment	AKT3	2.29
77	Bardet-biedl syndrome 16	Enrichment	AKT3	2.29
78	Smith-kingsmore syndrome	Enrichment	MTOR	2.29
79	Polycythemia	Enrichment	JAK2	2.29
80	Short stature due to growth hormone qualitative anomaly	Enrichment	GH1	2.29
81	Hypereosinophilic syndrome	Enrichment	JAK2	2.29
82	Laron syndrome with immunodeficiency	Enrichment	STAT5B	2.29
83	Wooly hair nevus	Enrichment	HRAS	2.29
84	Type 2 diabetes mellitus	Enrichment	AKT2, IL6	2.28
85	Gastric cancer	Enrichment	CDK4, KRAS	2.26
86	Hereditary breast carcinoma	Enrichment	AKT1, KRAS	2.24
87	Hyper-ige syndrome 1, autosomal dominant, with recurrent infections	Enrichment	STAT3	2.11
88	Immune thrombocytopenia	Enrichment	SOCS1	2.11
89	Polycythemia vera	Enrichment	JAK2	2.11
90	Tuberous sclerosis 1	Enrichment	IFNG	2.11
91	Langerhans cell histiocytosis	Enrichment	NRAS	2.11
92	Hepatitis c virus	Enrichment	IFNG	2.11
93	Tuberous sclerosis 2	Enrichment	IFNG	2.11
94	Immunodeficiency 28	Enrichment	IFNGR2	2.11
95	Autoinflammatory syndrome, familial, with or without immunodeficiency	Enrichment	SOCS1	2.11
96	Primary polycythemia	Enrichment	EPOR	2.11
97	Bacteremia 2	Enrichment	CISH	2.11
98	Hyper ige syndrome	Enrichment	STAT3	2.11
99	Dedifferentiated liposarcoma	Enrichment	CDK4	2.11
100	Isolated growth hormone deficiency, type ib	Enrichment	GH1	2.11
101	Spermatocytoma	Enrichment	HRAS	2.11
102	Well-differentiated liposarcoma	Enrichment	CDK4	2.11
103	Myeloma, multiple	Enrichment	CCND1, KRAS	2.04
104	Primary ovarian insufficiency	Enrichment	JAK2, PRLR	2.00
105	Kaposi sarcoma	Enrichment	IL6	1.99
106	Isolated growth hormone deficiency, type ii	Enrichment	GH1	1.99
107	Cardiofaciocutaneous syndrome 1	Enrichment	KRAS	1.99
108	Diffuse gastric and lobular breast cancer syndrome	Enrichment	KRAS	1.99
109	Anemia, autoimmune hemolytic	Enrichment	SOCS1	1.99
110	Budd-chiari syndrome	Enrichment	JAK2	1.99
111	Megalencephaly-capillary malformation-polymicrogyria syndrome	Enrichment	AKT3	1.99
112	Focal cortical dysplasia, type ii	Enrichment	MTOR	1.99
113	Mantle cell lymphoma	Enrichment	CCND1	1.99
114	Cardiofaciocutaneous syndrome	Enrichment	KRAS	1.99
115	Lung sarcomatoid carcinoma	Enrichment	KRAS	1.99
116	Hepatitis b	Enrichment	IFNGR1	1.99
117	Tuberculosis	Enrichment	CISH	1.99
118	Pilocytic astrocytoma	Enrichment	KRAS	1.99
119	Epidermolytic nevus	Enrichment	HRAS	1.99
120	Systemic-onset juvenile idiopathic arthritis	Enrichment	IL6	1.99
121	Isolated focal cortical dysplasia type ii	Enrichment	MTOR	1.99
122	Von hippel-lindau syndrome	Enrichment	CCND1	1.89
123	Rheumatoid arthritis, systemic juvenile	Enrichment	IL6	1.89
124	Myeloproliferative neoplasm	Enrichment	JAK2	1.89
125	Idiopathic aplastic anemia	Enrichment	IFNG	1.89
126	Type 1 diabetes mellitus	Enrichment	IL6	1.81
127	Chronic mucocutaneous candidiasis	Enrichment	STAT1	1.81
128	Lung squamous cell carcinoma	Enrichment	KRAS	1.81
129	Autosomal dominant secondary polycythemia	Enrichment	EPO	1.81
130	Breast cancer	Enrichment	AKT1, KRAS	1.80
131	Myelofibrosis	Enrichment	JAK2	1.75
132	Capillary malformation-arteriovenous malformation 1	Enrichment	KRAS	1.75
133	Renal cell carcinoma, papillary, 1	Enrichment	MTOR	1.75
134	Essential thrombocythemia	Enrichment	JAK2	1.75
135	Gallbladder cancer	Enrichment	KRAS	1.75
136	Pilomyxoid astrocytoma	Enrichment	KRAS	1.75
137	Megacolon	Enrichment	AKT3	1.75
138	Overgrowth syndrome	Enrichment	MTOR	1.75
139	Isolated growth hormone deficiency, type ia	Enrichment	GH1	1.69
140	Permanent neonatal diabetes mellitus	Enrichment	STAT3	1.69
141	Inflammatory bowel disease 1	Enrichment	IL6	1.64
142	Leukemia, acute lymphoblastic 3	Enrichment	JAK2	1.64
143	Arteriovenous malformation	Enrichment	HRAS	1.64
144	Cowden syndrome	Enrichment	AKT1	1.64
145	Leukemia, chronic lymphocytic	Enrichment	CCND1	1.59
146	Myopathy, x-linked, with excessive autophagy	Enrichment	HRAS	1.59
147	Aplastic anemia	Enrichment	IFNG	1.59
148	Polymicrogyria	Enrichment	AKT3	1.59
149	Ovarian cancer	Enrichment	AKT1, KRAS	1.56
150	Specific learning disability	Enrichment	GHR	1.55
151	Meningioma	Enrichment	AKT1	1.52
152	Lip and oral cavity carcinoma	Enrichment	HRAS	1.52
153	Hypercholesterolemia, familial, 1	Enrichment	GHR	1.48
154	Protein-deficiency anemia	Enrichment	NRAS	1.48
155	Lung cancer susceptibility 3	Enrichment	KRAS	1.45
156	Renal cell carcinoma, nonpapillary	Enrichment	MTOR	1.42
157	Familial hypercholesterolemia	Enrichment	GHR	1.42
158	Lynch syndrome	Enrichment	KRAS	1.42
159	Rare genetic intellectual disability	Enrichment	MTOR	1.42
160	Rhabdomyosarcoma	Enrichment	HRAS	1.39
161	Melanoma, cutaneous malignant 1	Enrichment	CDK4	1.37
162	Human immunodeficiency virus type 1	Enrichment	IFNG	1.34
163	Behcet syndrome	Enrichment	IFNGR1	1.32
164	Malaria	Enrichment	CISH	1.24
165	Pancreatic cancer	Enrichment	KRAS	1.20
166	Hydrops fetalis, nonimmune	Enrichment	HRAS	1.19
167	Lung cancer	Enrichment	KRAS	1.10
168	Systemic lupus erythematosus	Enrichment	SOCS1	1.02
169	Hereditary breast ovarian cancer syndrome	Enrichment	KRAS	0.88
170	Inherited cancer-predisposing syndrome	Enrichment	CDK4	0.54

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

JAK-STAT signaling in the regulation of Beta-cells

Pathway Network for JAK-STAT signaling in the regulation of Beta-cells

Member Pathways for JAK-STAT signaling in the regulation of Beta-cells

Pathways in the JAK-STAT signaling in the regulation of Beta-cells SuperPath

Associated Genes for JAK-STAT signaling in the regulation of Beta-cells

Associated Disorders for JAK-STAT signaling in the regulation of Beta-cells

Disorders associated with JAK-STAT signaling in the regulation of Beta-cells SuperPath

STRING Interaction Network for JAK-STAT signaling in the regulation of Beta-cells

Sources for JAK-STAT signaling in the regulation of Beta-cells